Table 1.
Baseline characteristics of 31,798 Veterans at risk of incident diabetes, 2000–2011.
| HIV + | HIV − | |||||
|---|---|---|---|---|---|---|
| N = 7177 | N = 24621 | p | ||||
| Age, years, Median (IQR) | 50 | (43,56) | 48 | (41,54) | <0.001 | |
| Male, N (%) | 6944 | (96.8) | 23813 | (96.7) | 0.88 | |
| Race, N (%) | White | 2592 | (36.1) | 10782 | (43.8) | <0.001 |
| Black | 3764 | (52.4) | 10692 | (43.4) | ||
| Hispanic | 453 | (6.3) | 1544 | (6.3) | ||
| Other/unknown | 368 | (5.1) | 1603 | (6.5) | ||
| BMI, kg/m2 | Underweight <18.5 | 332 | (4.6) | 276 | (1.1) | <0.001 |
| N(%) | Normal 18.5 to <25 | 3557 | (49.6) | 5378 | (21.8) | |
| Overweight 25 to <30 | 2322 | (32.4) | 9464 | (38.4) | ||
| Obese >= 30 | 966 | (13.5) | 9503 | (38.6) | ||
| Median (IQR) | 25 | (22,28) | 28 | (25,32) | <0.001 | |
| Smoking, N (%) | Never | 2006 | (28.0) | 7534 | (30.6) | <0.001 |
| Current | 4149 | (57.8) | 11854 | (48.1) | ||
| Former | 843 | (11.7) | 4456 | (18.1) | ||
| Unknown | 179 | (2.5) | 777 | (3.2) | ||
| Hepatitis C Infection, N (%) | 2303 | (32.1) | 3513 | (14.3) | <0.001 | |
| Start of follow-up, year |
2000–2002 | 1660 | (23.1) | 8336 | (33.9) | <0.001 |
| 2003–2005 | 1805 | (25.1) | 6610 | (26.8) | ||
| 2006–2008 | 1778 | (24.8) | 5166 | (21.0) | ||
| 2009–2011 | 1934 | (26.9) | 4509 | (18.3) | ||
| Median (IQR) | 2006 | ('03,'09) | 2004 | ('02,'08) | <0.001 | |
| Followed until | 5 years | 3533 | (49.2) | 13731 | (55.8) | |
| Last VA visit | 2763 | (38.5) | 7291 | (29.6) | <0.001 | |
| Incident diabetes | 357 | (5.0) | 2656 | (10.8) | ||
| Death | 524 | (7.3) | 943 | (3.8) | ||
| Total years, Median (IQR) | 4.9 | (2.6,5.0) | 5.0 | (3.0,5.0) | <0.001 | |
| CD4, cells/mm3, Median (IQR) | 218 | (85, 338) | NA | |||
| HIV-1 RNA, log copies/mL, Median (IQR) | 4.8 | (4.3, 5.3) | NA | |||
| ART regimen | NNRTI | 4321 | (60.2) | |||
| PI | 2503 | (34.9) | ||||
| Triple nucleoside | 353 | (4.9) | ||||
| AZT or D4T | 2886 | (40.2) | ||||
ART = Antiretroviral regimen, NNRTI = Non-nucleoside reverse transcriptase inhibitor, PI = Protease inhibitor